دورية أكاديمية
أعرض في EDS

Alpha-Melanocyte-Stimulating Hormone Maintains Retinal Homeostasis after Ischemia/Reperfusion.

التفاصيل البيبلوغرافية
العنوان: Alpha-Melanocyte-Stimulating Hormone Maintains Retinal Homeostasis after Ischemia/Reperfusion.
المؤلفون: Ng TF; Department of Ophthalmology, Boston University Chobanian & Avedesian School of Medicine, Boston, MA 02118, USA., Cho JY; Department of Ophthalmology, Boston University Chobanian & Avedesian School of Medicine, Boston, MA 02118, USA., Zhao JL; Department of Ophthalmology, Boston University Chobanian & Avedesian School of Medicine, Boston, MA 02118, USA., Gardiner JR; Department of Ophthalmology, Boston University Chobanian & Avedesian School of Medicine, Boston, MA 02118, USA., Wang ES; Department of Ophthalmology, Boston University Chobanian & Avedesian School of Medicine, Boston, MA 02118, USA., Leung E; Department of Ophthalmology, Boston University Chobanian & Avedesian School of Medicine, Boston, MA 02118, USA., Xu Z; Department of Ophthalmology, Boston University Chobanian & Avedesian School of Medicine, Boston, MA 02118, USA., Fineman SL; Department of Ophthalmology, Boston University Chobanian & Avedesian School of Medicine, Boston, MA 02118, USA., Lituchy M; Department of Ophthalmology, Boston University Chobanian & Avedesian School of Medicine, Boston, MA 02118, USA., Lo AC; Department of Ophthalmology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, China., Taylor AW; Department of Ophthalmology, Boston University Chobanian & Avedesian School of Medicine, Boston, MA 02118, USA.
المصدر: Biomolecules [Biomolecules] 2024 Apr 27; Vol. 14 (5). Date of Electronic Publication: 2024 Apr 27.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101596414 Publication Model: Electronic Cited Medium: Internet ISSN: 2218-273X (Electronic) Linking ISSN: 2218273X NLM ISO Abbreviation: Biomolecules Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI, 2011-
مواضيع طبية MeSH: alpha-MSH*/pharmacology , alpha-MSH*/metabolism , Reperfusion Injury*/metabolism , Reperfusion Injury*/pathology , Apoptosis*/drug effects , Retina*/metabolism , Retina*/drug effects , Retina*/pathology , Homeostasis*/drug effects , Retinal Ganglion Cells*/metabolism , Retinal Ganglion Cells*/drug effects , Retinal Ganglion Cells*/pathology, Animals ; Mice ; Mice, Inbred C57BL ; Microglia/metabolism ; Microglia/drug effects ; Male ; Ependymoglial Cells/metabolism ; Ependymoglial Cells/drug effects ; Ependymoglial Cells/pathology ; Disease Models, Animal ; Retinal Degeneration/metabolism ; Retinal Degeneration/pathology ; Retinal Degeneration/drug therapy
مستخلص: Augmenting the natural melanocortin pathway in mouse eyes with uveitis or diabetes protects the retinas from degeneration. The retinal cells are protected from oxidative and apoptotic signals of death. Therefore, we investigated the effects of a therapeutic application of the melanocortin alpha-melanocyte-stimulating hormone (α-MSH) on an ischemia and reperfusion (I/R) model of retinal degenerative disease. Eyes were subjected to an I/R procedure and were treated with α-MSH. Retinal sections were histopathologically scored. Also, the retinal sections were immunostained for viable ganglion cells, activated Muller cells, microglial cells, and apoptosis. The I/R caused retinal deformation and ganglion cell loss that was significantly reduced in I/R eyes treated with α-MSH. While α-MSH treatment marginally reduced the number of GFAP-positive Muller cells, it significantly suppressed the density of Iba1-positive microglial cells in the I/R retinas. Within one hour after I/R, there was apoptosis in the ganglion cell layer, and by 48 h, there was apoptosis in all layers of the neuroretina. The α-MSH treatment significantly reduced and delayed the onset of apoptosis in the retinas of I/R eyes. The results demonstrate that therapeutically augmenting the melanocortin pathways preserves retinal structure and cell survival in eyes with progressive neuroretinal degenerative disease.
References: Peptides. 1996;17(4):675-9. (PMID: 8804079)
Int Immunopharmacol. 2004 Aug;4(8):1059-66. (PMID: 15222980)
J Comp Neurol. 2008 Jul 10;509(2):225-38. (PMID: 18465787)
Neuroreport. 2020 Oct 7;31(14):1007-1014. (PMID: 32815825)
Immunity. 2019 Mar 19;50(3):723-737.e7. (PMID: 30850344)
Mediators Inflamm. 2016;2016:7368389. (PMID: 26949291)
Graefes Arch Clin Exp Ophthalmol. 2003 Dec;241(12):1044-50. (PMID: 14586589)
Physiol Rev. 2018 Oct 1;98(4):2381-2430. (PMID: 30156493)
Rom J Ophthalmol. 2015 Jul-Sep;59(3):133-6. (PMID: 26978879)
Eur J Immunol. 2006 Mar;36(3):754-69. (PMID: 16479540)
Eur J Pharmacol. 2016 Sep 15;787:84-93. (PMID: 27044435)
J Leukoc Biol. 2019 Oct;106(4):879-887. (PMID: 31287586)
Front Immunol. 2011 Sep 13;2:41. (PMID: 22566831)
Ophthalmic Res. 2023;66(1):1206-1212. (PMID: 37666222)
Transplantation. 2004 Dec 27;78(12):1756-64. (PMID: 15614148)
Mol Neurodegener. 2013 Jun 22;8:21. (PMID: 23800383)
PLoS One. 2014 Apr 02;9(4):e93433. (PMID: 24695675)
J Clin Med. 2022 Jul 07;11(14):. (PMID: 35887709)
J Vis Exp. 2016 Jul 14;(113):. (PMID: 27501124)
ASN Neuro. 2022 Jan-Dec;14:17590914221136365. (PMID: 36317314)
J Neurosci. 2002 Nov 1;22(21):9228-36. (PMID: 12417648)
Ophthalmic Res. 2005 Sep-Oct;37(5):279-88. (PMID: 16118510)
Eye Vis (Lond). 2015 Sep 30;2:17. (PMID: 26605370)
Biomolecules. 2024 Jan 31;14(2):. (PMID: 38397406)
J Neuroimmunol. 2011 Jul;236(1-2):1-9. (PMID: 21640392)
Invest Ophthalmol Vis Sci. 1999 Apr;40(5):967-75. (PMID: 10102294)
Ocul Immunol Inflamm. 2017 Apr;25(2):179-189. (PMID: 26807874)
Prog Retin Eye Res. 2004 Jan;23(1):91-147. (PMID: 14766318)
J Immunol. 2016 Dec 15;197(12):4626-4638. (PMID: 27849168)
J Immunol. 1989 Mar 1;142(5):1646-51. (PMID: 2537358)
Front Pharmacol. 2021 Sep 17;12:718902. (PMID: 34603029)
Prog Retin Eye Res. 2023 Jul;95:101187. (PMID: 37217094)
Methods Mol Biol. 2019;1899:211-227. (PMID: 30649775)
J Biol Chem. 2005 Feb 18;280(7):5795-802. (PMID: 15569680)
Biochem Biophys Res Commun. 2014 Jan 10;443(2):447-52. (PMID: 24316214)
Biochem Pharmacol. 2001 Mar 1;61(5):613-21. (PMID: 11239505)
Alzheimers Res Ther. 2015 Aug 19;7(1):56. (PMID: 26286145)
Prog Retin Eye Res. 2009 Nov;28(6):423-51. (PMID: 19660572)
Am J Physiol Endocrinol Metab. 2003 Mar;284(3):E468-74. (PMID: 12556347)
Invest Ophthalmol Vis Sci. 2004 Jan;45(1):159-64. (PMID: 14691168)
Am J Pathol. 2024 Jan;194(1):150-164. (PMID: 37827217)
Front Immunol. 2021 Aug 13;12:724601. (PMID: 34484232)
J Neuroinflammation. 2024 Mar 7;21(1):65. (PMID: 38454477)
J Immunol. 1996 Apr 1;156(7):2517-21. (PMID: 8786313)
Cell Cycle. 2019 Feb;18(4):413-424. (PMID: 30739530)
Int J Mol Sci. 2023 Apr 08;24(8):. (PMID: 37108092)
Mult Scler. 2013 Feb;19(2):130-6. (PMID: 23034287)
Cell Physiol Biochem. 2018;45(2):505-522. (PMID: 29402864)
J Endocrinol. 2007 Apr;193(1):157-69. (PMID: 17400813)
Front Pharmacol. 2019 Jan 14;9:1535. (PMID: 30692924)
Front Neurosci. 2022 Feb 25;16:799739. (PMID: 35281489)
J Exp Med. 2024 Mar 4;221(3):. (PMID: 38289348)
Int J Ophthalmol Eye Sci. 2015 Jan 29;Suppl 2(1):1-6. (PMID: 25905107)
Am J Pathol. 2020 Aug;190(8):1723-1734. (PMID: 32389572)
J Leukoc Biol. 2018 Feb 12;:. (PMID: 29431864)
J Endocrinol. 2001 Mar;168(3):527-37. (PMID: 11241184)
Zool Res. 2023 Jan 18;44(1):226-248. (PMID: 36594396)
Biochim Biophys Acta Mol Basis Dis. 2017 Oct;1863(10 Pt A):2462-2467. (PMID: 28499989)
Oxid Med Cell Longev. 2022 Jan 31;2022:4054938. (PMID: 35140838)
Invest Ophthalmol Vis Sci. 1997 Jun;38(7):1358-66. (PMID: 9191599)
Neoplasia. 2016 Jun;18(6):329-38. (PMID: 27292022)
Nat Rev Dis Primers. 2016 Mar 17;2:16012. (PMID: 27159554)
Immunol Today. 1997 Mar;18(3):140-5. (PMID: 9078687)
J Mol Neurosci. 2013 Jul;50(3):558-70. (PMID: 23504281)
Curr Diabetes Rev. 2024 Jan 24;:. (PMID: 38275038)
Curr Eye Res. 1992 Dec;11(12):1199-206. (PMID: 1490338)
معلومات مُعتمدة: R01 EY025961 United States EY NEI NIH HHS; none Boston University Chobanian & Avedisian School of Medicine Wing Tat Lee Award; none Massachusetts Lions Eye Research Fund
فهرسة مساهمة: Keywords: apoptosis; inflammation; ischemia/reperfusion; melanocortins; retinal degeneration
المشرفين على المادة: 581-05-5 (alpha-MSH)
تواريخ الأحداث: Date Created: 20240524 Date Completed: 20240524 Latest Revision: 20240605
رمز التحديث: 20240605
مُعرف محوري في PubMed: PMC11118772
DOI: 10.3390/biom14050525
PMID: 38785932
قاعدة البيانات: MEDLINE
الوصف
تدمد:2218-273X
DOI:10.3390/biom14050525